




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/04, 221/16, A61K 31/55, 31/435	A1	(11) International Publication Number: WO 98/57950 (43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/US98/11509 (22) International Filing Date: 15 June 1998 (15.06.98) (30) Priority Data: 08/877,052 17 June 1997 (17.06.97) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors: AFONSO, Adriano; 10 Woodmere Road, West Caldwell, NJ 07006 (US). KELLY, Joseph, M.; 112 Princeton Road, Parlin, NJ 08859 (US). WEINSTEIN, Jay; Apartment A6, 191 Bellevue Avenue, Upper Montclair, NJ 07043 (US). WOLIN, Ronald, L.; 42 Heatherwood Lane, Bedminister, NJ 07921 (US). ROSENBLUM, Stuart, B.; 16 Steven Terrace, West Orange, NJ 07052 (US). (74) Agents: MAJKA, Joseph, T. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NB, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL PHENYL-SUBSTITUTED TRICYCLIC INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE



(57) Abstract

Novel phenyl-substituted tricyclic compounds of formula (1.0) and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.